UPB
Upstream Bio, Inc.
NasdaqGSUSDEQUITY
Healthcare
DELAYED
Last price
6.84
▼ 0.01 (0.15%)
MARKET · —
Price
Open
6.98
Prev close
6.85
Day high
7.01
Day low
6.85
Volume
434.12K
Market cap
$381.75M
P/E (TTM)
—
52W range
5.85 – 33.68
Trailing performance
Returnvs SPY
1W
-1.41%
-0.0%
1M
+8.91%
+5.2%
3M
-17.61%
-20.7%
6M
-13.74%
-24.8%
YTD
-74.33%
-86.6%
1Y
-57.40%
-77.4%
3Y
—
-74.2%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Fundamentals
Market cap$381.75M
Enterprise value$121.40M
Revenue (TTM)$3.16M
Gross profit$3.16M
EBITDA$-169.78M
Net income$-156.50M
EPS (TTM)$-2.88
Free cash flow$-86.62M
Total cash$261.31M
Total debt$954.00K
Book value / share$5.59
Shares outstanding54.77M
Float42.81M
Short % of float10.24%
Dividend yield—
Beta (5Y)—
Valuation & profitability ratios
Trailing P/E—
Forward P/E-2.38
PEG ratio—
Price / sales—
Price / book1.25
EV / revenue38.44
EV / EBITDA-0.72
Gross margin100.00%
Operating margin-5480.98%
Profit margin0.00%
Return on equity-46.05%
Return on assets-30.28%
Debt / equity0.35
Current ratio27.99
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 |
|---|---|---|---|
| Total revenue | $2.85M | $2.37M | $0 |
| Cost of revenue | $0 | $0 | $0 |
| Gross profit | $0 | $0 | $0 |
| R&D | — | — | — |
| SG&A | — | — | — |
| Operating income | — | — | — |
| Pre-tax income | — | — | — |
| Tax provision | $0 | $0 | $0 |
| Net income | -$143.44M | -$62.81M | -$20.54M |
| EBIT | $0 | $0 | $0 |
| Line item | 2025 | 2024 | 2023 |
|---|---|---|---|
| Cash & equivalents | — | — | — |
| Short-term investments | — | — | — |
| Net receivables | — | — | — |
| Inventory | — | — | — |
| Total current assets | — | — | — |
| Total assets | — | — | — |
| Total current liabilities | — | — | — |
| Long-term debt | — | — | — |
| Total liabilities | — | — | — |
| Retained earnings | — | — | — |
| Shareholder equity | — | — | — |
| Line item | 2025 | 2024 | 2023 |
|---|---|---|---|
| Net income | -$143.44M | -$62.81M | -$20.54M |
| Depreciation | — | — | — |
| Change in working capital | — | — | — |
| Operating cash flow | — | — | — |
| Capital expenditure | — | — | — |
| Investing cash flow | — | — | — |
| Dividends paid | — | — | — |
| Buybacks | — | — | — |
| Financing cash flow | — | — | — |
| Net change in cash | — | — | — |
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | -0.76 | -0.73 | +4.1% |
| Dec 2025 | -0.70 | -0.78 | -11.6% |
| Sep 2025 | -0.77 | -0.63 | +17.8% |
| Jun 2025 | -0.61 | -0.74 | -21.2% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | -0.76 | 9 | $529.62K | -22.5% |
| Next quarter | -0.73 | 9 | $532.50K | -20.3% |
| Current year | -2.90 | 9 | $2.71M | -5.2% |
| Next year | -2.93 | 7 | $1.67M | -38.3% |
Analyst targets & ownership
Mean target$33.50
High target$75.00
Low target$9.00
Implied upside389.77%
Analyst count8
ConsensusBUY
Strong buy / Buy1 / 6
Hold2
Sell / Strong sell0 / 0
Held by insiders14.78%
Held by institutions92.52%
Institutions holding206
Price targets, consensus spread, insider and institutional ownership.
Insider net activity
Net shares
0
Net selling
Buy transactions
0
0 shares
Sell transactions
0
—
Net transactions
0
Buys less sells
Sell : buy shares
—
Not enough filings
Insider-held shares
8.10M
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Jun 16, 26 | GRAY MICHAEL P Chief Operating Officer |
SELL | 853 | $5.20K | Direct |
| Jun 16, 26 | SUTHERLAND EVERETT RAND Chief Executive Officer |
SELL | 2.10K | $12.78K | Direct |
| Jun 16, 26 | HOUGHTON ADAM Officer |
SELL | 700 | $4.27K | Direct |
| Jun 16, 26 | DEYKIN AARON Officer |
SELL | 895 | $5.46K | Direct |
| Jun 16, 26 | AMBROSE ALLISON General Counsel |
SELL | 477 | $2.91K | Direct |
| Mar 16, 26 | GRAY MICHAEL P Chief Operating Officer |
SELL | 852 | $7.92K | Direct |
| Mar 16, 26 | SUTHERLAND EVERETT RAND Chief Executive Officer |
SELL | 2.09K | $19.44K | Direct |
| Mar 16, 26 | HOUGHTON ADAM Officer |
SELL | 699 | $6.49K | Direct |
| Mar 16, 26 | DEYKIN AARON Officer |
SELL | 894 | $8.30K | Direct |
| Mar 16, 26 | AMBROSE ALLISON General Counsel |
SELL | 475 | $4.41K | Direct |
| Jan 2, 26 | GRAY MICHAEL P Chief Operating Officer |
STOCK | 30.50K | $0 | Direct |
| Jan 2, 26 | SUTHERLAND EVERETT RAND Chief Executive Officer |
STOCK | 75.00K | $0 | Direct |
| Jan 2, 26 | HOUGHTON ADAM Officer |
STOCK | 25.00K | $0 | Direct |
| Jan 2, 26 | DEYKIN AARON Officer |
STOCK | 32.00K | $0 | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
AI UPSTREAM LLC |
Beneficial Owner of more than 10% of a Class of Security | — | Conversion of Exercise of derivative security |
AMBROSE ALLISON |
General Counsel | 16.05K | Sale |
CHIMOVITS EREZ |
Director and Beneficial Owner of more than 10% of a Class of Security | — | Conversion of Exercise of derivative security |
DEYKIN AARON |
Officer | 33.20K | Sale |
GRAY MICHAEL P |
Chief Operating Officer | 28.80K | Sale |
HOUGHTON ADAM |
Officer | 23.60K | Sale |
ORBIMED ADVISORS, L.L.C. |
Director and Beneficial Owner of more than 10% of a Class of Security | — | Conversion of Exercise of derivative security |
SUTHERLAND EVERETT RAND |
Chief Executive Officer | 70.81K | Sale |
WELLINGTON BIOMEDICAL INNOVATION MASTER INVESTORS CAYMAN II |
Beneficial Owner of more than 10% of a Class of Security | 894.73K | Conversion of Exercise of derivative security |
Moving averages & technicals
SMA 10
7.07
-3.31% from price
SMA 20
6.85
+1.82% from price
SMA 50
6.85
+1.78% from price
SMA 100
7.88
-13.20% from price
SMA 200
14.76
-52.79% from price
EMA 12
7.00
-2.27% from price
EMA 26
6.96
-1.78% from price
EMA 50
7.21
-5.13% from price
RSI (14)
50.1
Neutral
MACD (12,26,9)
0.04
Hist 0.03
ATR (14)
0.46
6.58% of price
Realised vol 30D
57.4%
Annualised
Bollinger upper
7.53
20, 2σ
Bollinger lower
6.16
20, 2σ
50 / 200 cross
Death
6.85 vs 14.76
Trend bias
Below 200
-52.79%
Risk profile
Beta vs SPY
1.05
More volatile than market
Correlation to SPY
0.15
Largely independent
Realised vol 30D
57.4%
Annualised
Market vol 1Y
12.9%
SPY, annualised
Max drawdown 1Y
-81.8%
Peak to trough
Max drawdown 5Y
-81.8%
Peak to trough
ATR 14
0.46
6.58% of price
Beta (reported)
—
5Y monthly, from filing
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Options analytics
Put / call volume
1.60
Put-heavy session
Put / call open interest
1.14
Positioning, not flow
Max pain
7.50
+7.6% from spot
ATM implied vol
82.4%
Nearest strike to spot
Skew (10% OTM)
+18.9%
Puts bid over calls
Call volume
5
Contracts, this expiry
Put volume
8
Contracts, this expiry
Heaviest call OI
7.50
7 contracts
Heaviest put OI
7.50
6 contracts
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Headlines
Upstream Bio, Inc. (UPB) Reports Q2 Loss, Tops Revenue Estimates
Zacks · 11d ago
Upstream Bio Reports Second Quarter 2026 Financial Results and Highlights Continued Progress
GlobeNewswire · 11d ago
Upstream Bio, Inc. (UPB) Upgraded to Buy: What Does It Mean for the Stock?
Zacks · 39d ago
Is Upstream Bio, Inc. (UPB) a Rising Biotech Opportunity After New Analyst Coverage?
Insider Monkey · 58d ago
Is Upstream Bio, Inc. (UPB) the Best Low Priced Stocks to Get Rich in 2026?
Insider Monkey · 60d ago
Upstream Bio Presents New Responder Analyses Demonstrating Clinically Meaningful Improvements in CRSwNP in Significant Majority of Participants Treated with Verekitug in the Phase 2 VIBRANT Trial at EAACI 2026
GlobeNewswire · 69d ago
JPMorgan Downgrades Upstream Bio to Neutral From Overweight, Cuts Price Target to $8 From $35
MT Newswires · 71d ago
Upstream Bio to Showcase Additional Efficacy Data from the Phase 2 VIBRANT Trial of Verekitug in CRSwNP in Oral Session at EAACI 2026
GlobeNewswire · 75d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.